AMR Bio Launches with Phase III-Ready Antimicrobial

Announcement of the launch of a clinical-phase biotechnology company, which focuses on public health challenges while preventing infection where antibiotics are becoming less effective.

Announcement of the launch of a clinical-phase biotechnology company, which focuses on public health challenges while preventing infection where antibiotics are becoming less effective. It is advancing XF-73, a Phase 3-ready, first-in-class topical antimicrobial designed to prevent post-surgical infections by rapidly eliminating harmful bacteria before surgery.

According to Towards Healthcare, the UK biotechnology market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 126.45 billion in 2026 to approximately USD 336.82 billion by 2035, representing a compound annual growth rate (CAGR) of 11.5% from 2026 to 2035. Growth is driven by the rising demand for biologics and chronic disease treatments and massive investments in cutting-edge fields like AI-driven drug discovery and genomics. AMR Bio was established as a focused vehicle to advance the XF platform, combining dedicated leadership, capital, and discipline to progress XF-73 through final-stage development and towards commercialisation.

XF-73: Scientific Validation and Clinical Progress

XF-73 (exeporfinium chloride) is a synthetic, di-cationic porphyrin derivative. It is an innovative non-antibiotic mechanism that disrupts bacterial cell membranes, showing promise in combating resistant strains without fostering typical antibiotic resistance.

Regulatory progress includes the transfer of ownership and sponsorship of both the Investigational New Drug (IND) application for Nasal and the pre-Investigational New Drug (pIND) application for Dermal, along with the associated Qualified Infectious Disease Product (QIDP) designation and Fast Track status.

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) also granted XF-73 Nasal an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP), supporting an accelerated route to market and faster patient access for medicines targeting life-threatening conditions.

AMR Bio has also strengthened its execution through key partnerships, including the appointment of Cardinal Health as its US regulatory agent, and its membership of the BEAM Alliance, a network of biotech companies developing solutions to combat antimicrobial resistance.

A recent report by Towards Healthcare highlights that the UK biotechnology market is witnessing growth driven by the integration of AI in drug discovery, which is a major magnet for venture capital and strategic partnerships, and utilizes deep learning to map protein structures and design new treatments, supporting an accelerated route to market and faster patient access for medicines targeting life-threatening conditions.